SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-069346
Filing Date
2022-03-08
Accepted
2022-03-08 16:38:02
Documents
16
Period of Report
2022-03-03
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d305238d8k.htm   iXBRL 8-K 29074
2 EX-10.1 d305238dex101.htm EX-10.1 6187
3 EX-10.2 d305238dex102.htm EX-10.2 6939
4 EX-10.3 d305238dex103.htm EX-10.3 22925
8 GRAPHIC g305238dspp.jpg GRAPHIC 18257
  Complete submission text file 0001193125-22-069346.txt   227872

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA ikt-20220303.xsd EX-101.SCH 2850
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE ikt-20220303_lab.xml EX-101.LAB 18737
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ikt-20220303_pre.xml EX-101.PRE 11704
10 EXTRACTED XBRL INSTANCE DOCUMENT d305238d8k_htm.xml XML 3469
Mailing Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339
Business Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339 678-392-3419
Inhibikase Therapeutics, Inc. (Filer) CIK: 0001750149 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39676 | Film No.: 22722220
SIC: 2836 Biological Products, (No Diagnostic Substances)